Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
Search
PRRS Research Award 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Retinal health: All eyes on vision loss
Discover how we want to prevent vision loss caused by diabetic retinopathy and other retinal diseases
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Meet our team
Meet our team
GastroGard the first imported equine drug in China
GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Brigitte Fuhr
Brigitte Fuhr on constant innovation
Simon Manyara
Simon Manyara on constant innovation
Liliana Montano
Liliana Montano on constant innovation
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry
Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Zoonotic diseases things you should know
Zoonotic diseases can be transmitted between animals and humans. They are more common than you may think – and they are on the rise. Find out how this affects you.
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
Health, Safety & Environment
Suppliers shall provide a safe and healthy working environment and shall operate environmentally responsible and sustainable.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
More Potential Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.